Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuformix Plc ( (GB:NFX) ) has issued an update.
Nuformix PLC has announced an update on its total voting rights following the issuance of new ordinary shares. The company’s issued share capital now consists of 1,669,309,368 ordinary shares, each with one voting right, with no shares held in treasury. This update is in accordance with the FCA’s Disclosure Guidance and Transparency Rules, providing shareholders with the necessary information to determine their interests in the company. This announcement reflects Nuformix’s compliance with regulatory requirements and may influence shareholder decisions regarding their stakes in the company.
More about Nuformix Plc
Nuformix is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. The company leverages its expertise in discovering, developing, and patenting novel drug forms with improved physical properties to create differentiated products, offering new commercial opportunities. Nuformix’s pipeline includes preclinical assets with potential for significant value and early licensing opportunities.
YTD Price Performance: 80.0%
Average Trading Volume: 63,201,219
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.5M
See more data about NFX stock on TipRanks’ Stock Analysis page.